Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2020 Financial Results on March 10, 2021
BURLINGTON, Mass. , March 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after the close of the U.S. financial markets on Wednesday, March 10, 2021 .
View HTML
Toggle Summary Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301, a Novel Formulation of a Locally Administered NaV1.7 Inhibitor for Post-Operative Pain
FX301 combines NaV1.7 inhibitor (funapide) with a proprietary thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve block FX301 may provide 3 to 5 days of non-opioid pain relief while preserving motor function following musculoskeletal surgery Proof of concept Phase
View HTML
Toggle Summary Flexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors Conference
BURLINGTON, Mass. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 42 nd Annual Raymond James Institutional Investors Conference .
View HTML
Toggle Summary Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups
First-in-human single ascending dose trial advances to high dose cohort following positive Data Monitoring Committee review of mid dose safety data Company to expand FX201 low dose and mid dose cohorts to include up to 20 additional patients in each treatment group Flexion plans to present interim
View HTML
Toggle Summary National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA®
- Sheryl Swoopes, WNBA Legend, Basketball Hall of Famer and ZILRETTA Patient, Tips Off Educational Campaign About ZILRETTA and Osteoarthritis Knee Pain CHICAGO and BURLINGTON, Mass. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- The National Basketball Retired Players Association (NBRPA) and Flexion
View HTML
Toggle Summary Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results
Fourth-quarter 2020  ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales estimated to be approximately $26 .3 million Full-year 2020 net sales estimated to be approximately $85 .5 million Company names Adam Muzikant , Ph.D., Chief Business Officer BURLINGTON, Mass.
View HTML
Toggle Summary Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference
BURLINGTON, Mass. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the ICR | Westwicke Investment Conference . The virtual fireside
View HTML
Toggle Summary Flexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference
BURLINGTON, Mass. , Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of 22,798 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of
View HTML